Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharideviainactivation of nuclear factor-κB-Reference-Cited by-同舟云学术

Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharideviainactivation of nuclear factor-κB

Published:2014-05-22 Issue:3 Volume:36 Page:237-241
ISSN:0892-3973
Container-title:Immunopharmacology and Immunotoxicology
language:en
Short-container-title:Immunopharmacology and Immunotoxicology

Author:

Kato Yoshiro,Kamiya Hideki,Koide Naoki,Odkhuu Erdenezaya,Komatsu Takayuki,Dagvadorj Jargalsaikhan,Watarai Atsuko,Kondo Masaki,Kato Koichi,Nakamura Jiro,Yokochi Takashi

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.3109/08923973.2014.921690

Reference25 articles.

1. The spironolactone renaissance

2. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

3. Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats

4. Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet

5. Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the role of aldosterone in glycation-induced diabetic complications;Biochemical and Biophysical Research Communications;2024-08

2. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease;Advanced Biology;2023-12-08

3. Immunomodulatory Potential of Diuretics;Biology;2021-12-11

4. Therapeutic potential of spironolactone in ankylosing spondylitis patients: Relation to disease activity and functional status;The Egyptian Rheumatologist;2021-04

5. Role of mineralocorticoid receptor antagonists in kidney diseases;Drug Development Research;2020-11-12